Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

R A Koup, J T Safrit, Y Cao, C A Andrews, G McLeod, W Borkowsky, C Farthing, D D Ho, R A Koup, J T Safrit, Y Cao, C A Andrews, G McLeod, W Borkowsky, C Farthing, D D Ho

Abstract

Virologic and immunologic studies were performed on five patients presenting with primary human immunodeficiency virus type 1 (HIV-1) infection. CD8+ cytotoxic T lymphocyte (CTL) precursors specific for cells expressing antigens of HIV-1 Gag, Pol, and Env were detected at or within 3 weeks of presentation in four of the five patients and were detected in all five patients by 3 to 6 months after presentation. The one patient with an absent initial CTL response had prolonged symptoms, persistent viremia, and low CD4+ T-cell count. Neutralizing antibody activity was absent at the time of presentation in all five patients. These findings suggest that cellular immunity is involved in the initial control of virus replication in primary HIV-1 infection and indicate a role for CTL in protective immunity to HIV-1 in vivo.

References

    1. J Virol. 1993 Apr;67(4):1772-7
    1. J Exp Med. 1991 May 1;173(5):1053-63
    1. Nature. 1993 Mar 25;362(6418):359-62
    1. Science. 1993 Mar 19;259(5102):1749-54
    1. Science. 1993 Aug 27;261(5125):1179-81
    1. J Exp Med. 1994 Feb 1;179(2):463-72
    1. J Virol. 1994 Apr;68(4):2362-70
    1. J Immunol Methods. 1982 Mar 12;49(2):R11-23
    1. N Engl J Med. 1982 Jul 1;307(1):7-13
    1. J Exp Med. 1984 Sep 1;160(3):814-26
    1. J Virol. 1984 Sep;51(3):682-6
    1. J Exp Med. 1985 Jan 1;161(1):40-52
    1. Science. 1986 Dec 19;234(4783):1563-6
    1. Cell. 1987 Jan 30;48(2):231-40
    1. Lancet. 1987 Jan 17;1(8525):119-22
    1. Nature. 1987 Jul 23-29;328(6128):345-8
    1. J Virol. 1987 Oct;61(10):3102-8
    1. Science. 1988 Apr 1;240(4848):64-6
    1. J Immunol. 1989 Jan 15;142(2):452-62
    1. J Virol. 1989 Feb;63(2):584-90
    1. J Exp Med. 1989 Apr 1;169(4):1421-34
    1. J Virol. 1989 May;63(5):2270-7
    1. Blood. 1989 May 15;73(7):1909-14
    1. N Engl J Med. 1989 Jun 29;320(26):1731-5
    1. J Immunol. 1989 Jul 15;143(2):660-70
    1. N Engl J Med. 1991 Apr 4;324(14):961-4
    1. J Exp Med. 1991 Dec 1;174(6):1593-600
    1. J Virol. 1992 Jan;66(1):608-11
    1. AIDS. 1991 Nov;5(11):1309-14
    1. Nature. 1992 Feb 20;355(6362):728-30
    1. AIDS Res Hum Retroviruses. 1991 Dec;7(12):971-3
    1. AIDS. 1992 Aug;6(8):799-802
    1. Lancet. 1992 Nov 21;340(8830):1257-8
    1. Lancet. 1993 Jan 9;341(8837):113
    1. J Exp Med. 1993 Feb 1;177(2):249-56
    1. J Exp Med. 1993 Feb 1;177(2):317-27
    1. J Virol. 1993 Mar;67(3):1707-11
    1. AIDS. 1993 Jan;7(1):15-21
    1. Immunol Today. 1989 Mar;10(3):79-86
    1. N Engl J Med. 1989 Dec 14;321(24):1621-5
    1. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9514-8
    1. AIDS. 1990 Feb;4(2):107-12
    1. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6574-8
    1. J Virol. 1991 Jan;65(1):489-93
    1. N Engl J Med. 1991 Apr 4;324(14):954-60
    1. Int Immunol. 1990;2(8):707-12
    1. Nature. 1993 Mar 25;362(6418):355-8

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi